Skip to main content

Eli Lilly Alzheimer's treatment solanezumab failed to slow disease progression

Solanezumab's failure is a blow to efforts to treat Alzheimer's in people who have not yet shown clinical symptoms.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.